Get started
Author

JeeHye Suh

Observed names: Jeehye Suh, Suh, JeeHye
Observed institution: Celltrion (South Korea)
ORCID: 0009-0005-9273-0784
Observed ORCID: 0009-0005-9273-0784
OpenAlex ID: A5110545230
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis
2024 · Jean-Yves Reginster, Edward Czerwinski, et al. · Osteoporosis International · 21
Fri0128 a Novel Formulation of Ct-p13 (infliximab Biosimilar) for Subcutaneous Administration: 1-year Results From a Part 1 of Phase I/iii Randomized Controlled Trial in Patients With Active Rheumatoid Arthritis
2019 · DaeHyun Yoo, Janusz Jaworski, et al. · Annals of the Rheumatic Diseases · 12
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males
2024 · Anhye Kim, Jang Hee Hong, et al. · Expert Opinion on Biological Therapy · 8
PDF
Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis
2025 · Gerd Burmester, Jakub Trefler, et al. · Clinical Drug Investigation · 5
PDF
Sat0170 a Novel Formulation of Ct-p13 for Subcutaneous Administration: 30 Week Results From a Part 2 of Phase I/iii Randomized Controlled Trial in Patients With Rheumatoid Arthritis
2019 · Rene Westhovens, Piotr Wiland, et al. · Annals of the Rheumatic Diseases · 5
PDF
Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study
2024 · Miwa Haranaka, Takashi Eto, et al. · The Journal of Clinical Pharmacology · 3
PDF
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
2025 · David M. Pariser, Mark G. Lebwohl, et al. · Dermatology and Therapy · 1
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
2026 · Hasunuma, Tomoko, Yagi, Michio, et al. · Figshare
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
2026 · Tomoko Hasunuma, Michio Yagi, et al. · Expert Opinion on Investigational Drugs
PDF
Works count: 11
Citation count: 55
H-index: 5
I10-index: 2
Year
Topic
Type